| Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib A Gángó, D Alpár, B Galik, D Marosvári, R Kiss, V Fésüs, D Aczél, ... International Journal of Cancer 146 (1), 85-93, 2020 | 54 | 2020 |
| Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia M Koszarska, A Bors, A Feczko, N Meggyesi, A Batai, J Csomor, E Adam, ... Leukemia & lymphoma 54 (5), 1028-1035, 2013 | 47 | 2013 |
| Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia … N Meggyesi, A Kozma, G Halm, S Nahajevszky, A Batai, S Fekete, A Barta, ... Acta Haematologica 127 (1), 34-42, 2012 | 42 | 2012 |
| First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR–ABL transcripts H Andrikovics, S Nahajevszky, A Szilvási, A Bors, E Adám, A Kozma, ... Hematological oncology 25 (3), 143-147, 2007 | 39 | 2007 |
| JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia H Andrikovics, S Nahajevszky, M Koszarska, N Meggyesi, A Bors, G Halm, ... Leukemia 24 (10), 1809-1813, 2010 | 38 | 2010 |
| Hepatosplenic γδ T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration J Tamaska, E Adam, A Kozma, L Gopcsa, H Andrikovics, A Tordai, ... Virchows Archiv 449, 479-483, 2006 | 34 | 2006 |
| In vitro expansion of long-term repopulating hematopoietic stem cells in the presence of immobilized Jagged-1 and early acting cytokines Z Kertész, V Vas, J Kiss, VS Urbán, É Pozsonyi, A Kozma, K Pálóczi, ... Cell biology international 30 (5), 401-405, 2006 | 33 | 2006 |
| The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia S Nahajevszky, H Andrikovics, A Batai, E Adam, A Bors, J Csomor, ... Haematologica 96 (11), 1613, 2011 | 25 | 2011 |
| Reduction of Bcr‐Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK A Brózik, NP Casey, C HEGEDŰS, A Bors, A Kozma, H Andrikovics, ... Annals of the New York Academy of Sciences 1090 (1), 344-354, 2006 | 24 | 2006 |
| Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort M Koszarska, N Meggyesi, A Bors, A Batai, O Csacsovszki, E Lehoczky, ... Leukemia & Lymphoma 55 (7), 1510-1517, 2014 | 21 | 2014 |
| Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin H Skribek, R Otvos, E Flaberg, N Nagy, L Markasz, S Eksborg, T Masszi, ... Experimental hematology 38 (12), 1219-1230, 2010 | 19 | 2010 |
| NFKB1 −94ins/delATTG polymorphism is a novel prognostic marker in first line‐treated multiple myeloma G Varga, G Mikala, H Andrikovics, M Koszarska, K Balassa, E Ádám, ... British Journal of Haematology 168 (5), 679-688, 2015 | 16 | 2015 |
| Lipoprotein lipase as a prognostic marker in chronic lymphocytic leukemia Z Mátrai, H Andrikovics, A Szilvási, A Bors, A Kozma, E Ádám, G Halm, ... Pathology & Oncology Research 23, 165-171, 2017 | 13 | 2017 |
| Targeted venetoclax therapy in t (11; 14) multiple myeloma: real world data from seven Hungarian centers VR Szita, G Mikala, A Kozma, J Fábián, A Hardi, H Alizadeh, P Rajnics, ... Pathology and Oncology Research, 15, 2022 | 9 | 2022 |
| Monoklonális ellenanyag-alapú terápia myeloma multiplexben A Hardi, A Kozma, A Ceglédi, Á Tomán, A Bors, H Andrikovics, G Mikala Hematológia–Transzfuziológia 54 (1), 27-36, 2021 | 8 | 2021 |
| Biodiversity of algae of the upper and middle course of the Olt River A Rasiga, L Momeu, Ş Péterfi, A Kozma Transylvanian Review of Systematical and Ecological Research, 31-48, 1999 | 6 | 1999 |
| Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia P Kövy, Z Őrfi, A Bors, A Kozma, L Gopcsa, J Dolgos, N Lovas, ... Plos one 16 (6), e0253386, 2021 | 5 | 2021 |
| Új terápiás célpont akut myeloid leukémiában: izocitrát dehidrogenáz 1 és 2 mutációk P Kövy, A Kozma, A Bors, N Meggyesi, E Ádám, A Borsy, J Dolgos, ... Hematológia–Transzfuziológia 52 (2), 106-114, 2019 | 4 | 2019 |
| A mielodiszpláziás szindróma kariotípus-eltérései; biológiai és terápiás következményeik A Kozma, M Paksi, E Ádám, A Bors, H Andrikovics, G Mikala Hematológia–Transzfuziológia 52 (1), 19-27, 2019 | 2 | 2019 |
| The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma KP Kiss, G Varga, G Mikala, K Balassa, A Bors, P Kovy, N Meggyesi, ... Leukemia & Lymphoma 59 (3), 710-716, 2018 | 2 | 2018 |
